Home »
Socio-economic Nomenclature and Categories of Fiscal Corruption
» Bail In Proposition
Bail In Proposition
Written By Michael Reign on Monday, February 3, 2014 | 8:34 PM
| Clinical Diagnosis | Count |
|---|---|
| Arthralgia | 33,837 |
| Lymphadenopathy | 18,560 |
| Tinnitus | 6,790 |
| Syncope | 5,373 |
| COVID-19¹ | 4,087 |
| Vertigo | 3,945 |
| Epistaxis | 3,366 |
| Shingles (Herpes Zoster) | 3,278 |
| Seizures | 2,131 |
| Premature Deaths | 1,945 |
| Hypertension (High Blood Pressure) | 1,794 |
| Myocarditis/ Pericarditis | 1,633 |
| Anaphylaxis³ | 1,522 |
| Thrombocytopenia/ Platelet Deficiency² | 1,487 |
| Bell’s Palsy | 1,252 |
| Heart Attacks/ Cardiac Arrest⁴ | 1,195 |
| Hypotension (Low Blood Pressure) | 1,018 |
| Neoplasms⁵ | 867 |
| Miscarriages⁶ | 703 |
| Guillain-Barré Syndrome (GBS) | 584 |
| Paralysis | 510 |
| Sepsis | 186 |
| Lupus⁷ | 69 |
| Stillbirth/ Fetal Death | 19 |
| Lyme Disease | 12 |
| AIDS | 3 |
| SOC TOTAL | 1,337,933 |
| Clinical Diagnosis | Count |
|---|---|
| Permanent Disability | 44,512 |
| Severe Allergy | 40,123 |
| Myocarditis/ Pericarditis | 34,448 |
| Thromboses (Blood Clots)/ Strokes¹ | 31,727 |
| Syncope | 29,133 |
| Premature Deaths | 24,402 |
| Tinnitus | 19,045 |
| Bell’s Palsy | 14,157 |
| Vertigo | 13,039 |
| Shingles (Herpes Zoster) | 12,566 |
| Heart Attacks/ Cardiac Arrest | 12,511 |
| Anaphylaxis | 9,262 |
| Infarction² | 9,191 |
| Thrombocytopenia/ Platelet Deficiency | 5,725 |
| Miscarriages | 4,142 |
| Permanent Hearing Loss | 2,552 |
| Sepsis | 1,832 |
| Cancer³ | 703 |
| Lupus⁴ | 433 |
| Lyme Disease | 326 |
| Amputations | 64 |
| AIDS | 6 |
| TOTAL | 1,134,982 |
| Adverse Reaction | MedAlerts.org | OpenVAERS |
|---|---|---|
| Anaphylaxis | 42,265 | 9,262 |
| Bell’s Palsy | 9,006 | 14,157 |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| CSL Limited* | 1 | 0.002% |
| Dynavax Technologies Corporation | 1 | 0.002% |
| GlaxoSmithKline Biologicals | 32 | 0.08% |
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 1,954 | 4.62% |
| MedImmune Vaccines, Inc.** | 2 | 0.005% |
| Merck & Co. Inc. | 8 | 0.02% |
| Moderna Therapeutics | 17,009 | 40.24% |
| Novartis Vaccines and Diagnostics | 1 | 0.002% |
| Pfizer/ BioNTech | 24,219 | 57.3% |
| Protein Sciences Corporation*** | 5 | 0.01% |
| Sanofi Pasteur/ Translate Bio | 26 | 0.06% |
| Seqirus, Inc.**** | 37 | 0.09% |
| Teva Pharmaceuticals USA, Inc.***** | 1 | 0.002% |
| Undisclosed Manufacturers | 342 | 0.81% |
| TOTAL | †43,638 | †103.25% |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| CSL Limited | 1 | 0.04% |
| GlaxoSmithKline Biologicals | 5 | 0.22% |
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 442 | 19.1% |
| Merck & Co., Inc. | 1 | 0.04% |
| Moderna Therapeutics | 447 | 19.32% |
| Pfizer/ BioNTech | 1,481 | 64% |
| Sanofi Pasteur/ Translate Bio | 4 | 0.17% |
| Seqirus, Inc. | 1 | 0.04% |
| Undisclosed Manufacturers | 33 | 1.43% |
| TOTAL | †2,415 | †104.36% |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| GlaxoSmithKline Biologicals | 5 | 0.06% |
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 469 | 5.21% |
| Merck & Co. Inc. | 4 | 0.04% |
| Moderna Therapeutics | 1,957 | 21.73% |
| Novartis Vaccines and Diagnostics | 2 | 0.02% |
| Pfizer/ BioNTech | 6,808 | 75.59% |
| Protein Sciences Corporation | 1 | 0.01% |
| Sanofi Pasteur/ Translate Bio | 4 | 0.04% |
| Seqirus, Inc. | 3 | 0.03% |
| Undisclosed Manufacturers | 71 | 0.79% |
| TOTAL | †9,324 | †103.53% |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 174 | 9.46% |
| Merck & Co. Inc. | 1 | 0.05% |
| Moderna Therapeutics | 474 | 25.76% |
| Pfizer/ BioNTech | 1,239 | 67.34% |
| Sanofi Pasteur/ Translate Bio | 1 | 0.05% |
| Seqirus, Inc. | 2 | 0.11% |
| Undisclosed Manufacturers | 18 | 0.98% |
| TOTAL | †1,909 | †103.75% |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| GlaxoSmithKline Biologicals | 3 | 0.17% |
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 176 | 9.84% |
| Merck & Co. Inc. | 4 | 0.22% |
| Moderna Therapeutics | 435 | 24.32% |
| Novartis Vaccines and Diagnostics | 1 | 0.06% |
| Pfizer/ BioNTech | 1,215 | 67.92% |
| Sanofi Pasteur/ Translate Bio | 2 | 0.11% |
| Seqirus, Inc. | 1 | 0.06% |
| Undisclosed Manufacturers | 18 | 1.01% |
| TOTAL | †1,855 | †103.69% |
| Vaccine Manufacturer | Count | Percentageᴬ |
|---|---|---|
| CSL Limited | 1 | 0.004% |
| GlaxoSmithKline Biologicals | 10 | 0.04% |
| Johnson & Johnson (Janssen Pharmaceutical Companies) | 2,188 | 8.97% |
| MedImmune Vaccines, Inc. | 1 | 0.004% |
| Merck & Co., Inc. | 1 | 0.004% |
| Moderna Therapeutics | 6,936 | 28.42% |
| Novartis Vaccines and Diagnostics | 5 | 0.02% |
| Pfizer/ BioNTech | 17,245 | 70.67% |
| Protein Sciences Corporation | 1 | 0.004% |
| Sanofi Pasteur/ Translate Bio | 17 | 0.07% |
| Seqirus, Inc. | 6 | 0.02% |
| Undisclosed Manufacturers | 388 | 1.59% |
| TOTAL | †26,799 | †109.82% |
| Chronological Age | Count | Percentage |
|---|---|---|
| Under 3 Years | 4 | 0.02% |
| 3-6 Years | 1 | 0.004% |
| 6-9 Years | 2 | 0.008% |
| 9-12 Years | 1 | 0.004% |
| 12-17 Years | 59 | 0.24% |
| 17-44 Years | 968 | 3.97% |
| 44-65 Years | 2,962 | 12.14% |
| 65-75 Years | 3,460 | 14.18% |
| 75+ Years | 7,687 | 31.5% |
| Undisclosed | 9,258 | 37.94% |
| TOTAL | 24,402 | 100% |
0 comments:
Speak your mind and let your voice be heard.
This is a censorship free discussion area, however, any comments that deviate from the content presented on this site will be subject to removal without notice.